Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-15T08:50:23.057Z Has data issue: false hasContentIssue false
  • English
  • Français

Probiotics and bowel inflammation

Review products

HH.Cui et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004 May 15;10(10):1521–5.
HJ.Kim et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005 Oct;17(5):687–96.
KO.Laake et al. Outcome of four weeks’ intervention with probioticson symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol. 2005 Jan;40(1):43–51.

Published online by Cambridge University Press:  11 September 2013

Get access

In a nutshell

Inflammatory bowel diseases can involve problems in the development of the gut's immune response. A healthy bowel flora plays an important role in this development, for example through effects on cytokines.

Clinical trials of probiotics for IBD have been predominantly positive for ulcerative colitis and pouchitis, less so for Crohn's disease. So far probiotics appear to be a notably safe therapy, although some theoretical safety issues need to be borne in mind.

Information

Type
Brief Report
Information
Arbor Clinical Nutrition Updates , Volume 247 , March 2006, pp. 1 - 4
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Bousvaros, A. et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005 Sep;11(9):833–9.Google Scholar
2. Schultz, M. et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004 Mar 15;4:5.Google Scholar
3. Guslandi, M. et al. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003 Jun;15(6):697–8.Google Scholar
4. Guslandi, M. et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000 Jul;45(7):1462–4.CrossRefGoogle ScholarPubMed
5. Prantera, C. et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002 Sep;51(3):405–9.Google Scholar
6. O'Mahony, L. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005 Mar;128(3):541–51.Google Scholar
7. Niv, E. et al. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clin Nutr. 2005 Dec;24(6):925–31.Google Scholar
8. Cui, HH. et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004 May 15;10(10):1521–5.CrossRefGoogle ScholarPubMed
9. Kajander, K. et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005 Sep 1;22(5):387–94.CrossRefGoogle ScholarPubMed
10. Bausserman, M. et al. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005 Aug;147(2):197–201.Google Scholar
11. Bittner, AC. et al. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther. 2005 Jun;27(6):755–61.Google Scholar
12. Shen, B. et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005 Oct 15;22(8):721–8.Google Scholar
13. Kim, HJ. et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005 Oct;17(5):687–96.Google Scholar
14. Laake, KO. et al. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). Scand J Gastroenterol. 2004 Dec;39(12):1228–35.Google Scholar
15. Gionchetti, P. et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003 May;124(5):1202–9.Google Scholar
16. Laake, KO. et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol. 2003 Apr;38(4):409–14.Google Scholar
17. Bibiloni, R. et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005 Jul;100(7):1539–46.Google Scholar
18. Furrie, E. et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005 Feb;54(2):242–9.Google Scholar
19. Kruis, W. et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997 Oct;11(5):853–8.Google Scholar
20. Kato, K. et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1133–41.Google Scholar
21. Kruis, W. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004 Nov;53(11):1617–23.Google Scholar
22. Tursi, A. et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004 Nov;10(11):PI 126–31.Google Scholar
23. Laake, KO. et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol. 2005 Jan;40(1):43–51.Google Scholar
24. Hanai, H. et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med. 2004 May;13(5):643–7.Google Scholar
25. Ishikawa, H. et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003 Feb;22(1):56–63.Google Scholar
26. Rembacken, BJ. et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999 Aug 21;354(9179):635–9.Google Scholar
27. Venturi, A. et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999 Aug;13(8):1103–8.Google Scholar
28. Karimi, O. et al. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. Drugs Today (Barc). 2005 Jul;41(7):453–9.Google Scholar
29. Korzenik, JR. et al. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov. 2006 Mar;5(3):197–209.Google Scholar
30. Rook, GA. et al. Microbes, immunoregulation, and the gut. Gut. 2005 Mar;54(3):317–20.Google Scholar
31. Jonkers, D. et al. Probiotics and inflammatory bowel disease. J R Soc Med. 2003 Apr;96(4):167–71.CrossRefGoogle ScholarPubMed
32. Campieri, M. et al. Bacteria as the cause of ulcerative colitis. Gut. 2001 Jan;48(1):132–5.Google Scholar
33. Ghosh, S. et al. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut. 2004 May;53(5):620–2.Google Scholar
34. Ingrassia, I. et al. Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol. 2005 Jun;71(6):2880–7.CrossRefGoogle ScholarPubMed
35. Ezendam, J. et al. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev. 2006 Jan;64(1):1–14.Google Scholar
36. Senok, AC. et al. Probiotics: facts and myths. Clin Microbiol Infect. 2005 Dec;11(12):958–66.Google Scholar
37. Helman, A. Probiotics, immunity and allergy. Arbor Clin Nutr Updates. 2006;246:1–5.Google Scholar